Mohali, Punjab, India, August 22, 2016 --(PR.com
)-- Roots Analysis has announced the addition of “Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026” report to its portfolio. The report provides a comprehensive analysis of the current market landscape of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. It also features a detailed forecast of the likely evolution of the market over the next decade.
Kashish Goel, the principal analyst, said, “The chronic and progressive nature of diabetes has spurred significant efforts dedicated to the development of novel therapies to offer better treatment options for diabetics worldwide. Currently, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors represent the most popular classes of non-insulin therapies. A number of blockbuster drugs have emerged from these classes; examples include VICTOZA®, JANUVIA® / JANUMET® and INVOKANA® / INVOKAMET®.”
The report offers elaborate research, analysis and opinions on several areas; these include:
-An overview of the overall market landscape highlighting important details, such as routes of administration, dosage frequency, type of molecules and key stakeholders, on molecules related to different drug classes.
-Detailed profiles of drugs that have been recently approved / marketed or are in the late stages of development.
-Information on the key opinion leaders (KOLs) involved in the discovery and development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors.
-An analysis of recently published clinical trial data, depicting prevalent trends and technological developments.
-A discussion on the side effects of currently available non-insulin therapies and regulatory guidelines for future drug development.
-A list of upcoming non-insulin therapies that are likely to play a significant role in the anti-diabetic drugs market in the near future.
-An estimate of the future size of the non-insulin therapies for diabetes market, including the expected future sales of both marketed and late stage products belonging to the GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors.
Goel further stated, “Drug developers continue to investigate alternate routes of administration and novel indications for these drug classes. Several innovative technology platforms have been developed to facilitate the oral or nasal delivery of GLP-1 agonists. Oral capsule formulations of DPP4 inhibitors have also been developed. Likewise, certain SGLT2 inhibitors are being evaluated for the treatment of type I diabetes. In addition, dual agonist drugs have also been developed to provide more effective treatment options.”
The report is likely to benefit big and small pharma companies involved in the development of anti-diabetic therapies. In particular, you could benefit if you are an:
CXO level decision maker
Business Intelligence / Scientific Analyst
Licensing / Portfolio Manager
For additional details, please visit
or email email@example.com
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at firstname.lastname@example.org